These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28810116)

  • 1. Stop the Bleeding! Reversing the Effects of Direct-acting Oral Anticoagulants.
    Fischer J
    S D Med; 2016 Nov; 69(11):516-517. PubMed ID: 28810116
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antidotes for the new oral anticoagulants: Reality and expectations].
    Gómez-Outes A; Lecumberri R
    Med Clin (Barc); 2016 Jun; 146(11):488-90. PubMed ID: 26776485
    [No Abstract]   [Full Text] [Related]  

  • 3. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
    Levy JH; Ageno W; Chan NC; Crowther M; Verhamme P; Weitz JI;
    J Thromb Haemost; 2016 Mar; 14(3):623-7. PubMed ID: 26911798
    [No Abstract]   [Full Text] [Related]  

  • 4. [First NOAK with specific antidote].
    Einecke D
    MMW Fortschr Med; 2015 Dec; 157(21-22):84. PubMed ID: 26960882
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
    Pollack CV
    Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
    [No Abstract]   [Full Text] [Related]  

  • 6. [First NOAk specific antidote as additional safety factor in therapy].
    MMW Fortschr Med; 2016 Feb; 158(2):66-7. PubMed ID: 27017635
    [No Abstract]   [Full Text] [Related]  

  • 7. Specific antidotes for bleeding associated with direct oral anticoagulants.
    Burnett A; Siegal D; Crowther M
    BMJ; 2017 May; 357():j2216. PubMed ID: 28546438
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and Treatment of Bleeding with Direct Oral Anticoagulants.
    Crawley RM; Anderson RL
    Drugs; 2020 Sep; 80(13):1293-1308. PubMed ID: 32691292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to direct oral anticoagulants and rationale for specific reversal agents.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):1-2. PubMed ID: 27697437
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical and clinical data for factor Xa and "universal" reversal agents.
    Milling TJ; Kaatz S
    Am J Emerg Med; 2016 Nov; 34(11S):39-45. PubMed ID: 27697443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Throwing it in reverse: An update on reversal of oral factor Xa inhibitors.
    Gilbert BW; Reeder JA; Alkhalifah MA; Moran DA; Corvino MA
    Am J Emerg Med; 2019 Oct; 37(10):1978-1980. PubMed ID: 30987915
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis.
    Heidinger KS; Bernardo A; Taborski U; Müller-Berghaus G
    Thromb Res; 2000 May; 98(4):287-93. PubMed ID: 10822075
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticoagulation in patients with advanced liver disease: an open issue.
    Violi F; Loffredo L; Pastori D
    Intern Emerg Med; 2021 Jan; 16(1):61-71. PubMed ID: 33073317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Tomaselli GF; Mahaffey KW; Cuker A; Dobesh PP; Doherty JU; Eikelboom JW; Florido R; Hucker W; Mehran R; Messé SR; Pollack CV; Rodriguez F; Sarode R; Siegal D; Wiggins BS
    J Am Coll Cardiol; 2017 Dec; 70(24):3042-3067. PubMed ID: 29203195
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.